Gubra A/S Stock

Equities

GUBRA

DK0062266474

Biotechnology & Medical Research

Market Closed - Nasdaq Copenhagen 10:59:38 2024-04-26 am EDT 5-day change 1st Jan Change
282 DKK +1.81% Intraday chart for Gubra A/S -0.35% +125.60%
Sales 2022 199M 28.59M Sales 2023 205M 29.4M Capitalization 2.04B 292M
Net income 2022 4M 574K Net income 2023 -44M -6.31M EV / Sales 2022 * -
Net cash position 2022 2.52M 362K Net cash position 2023 386M 55.35M EV / Sales 2023 8.05 x
P/E ratio 2022 *
-
P/E ratio 2023
-42.6 x
Employees 220
Yield 2022 *
-
Yield 2023
-
Free-Float 30.58%
More Fundamentals * Assessed data
Dynamic Chart
1 day+1.81%
1 week-0.35%
Current month-3.09%
1 month+8.46%
3 months+133.06%
6 months+179.26%
Current year+125.60%
More quotes
1 week
273.00
Extreme 273
300.00
1 month
266.00
Extreme 266
324.00
Current year
114.00
Extreme 114
346.00
1 year
83.45
Extreme 83.45
346.00
3 years
83.45
Extreme 83.45
346.00
5 years
83.45
Extreme 83.45
346.00
10 years
83.45
Extreme 83.45
346.00
More quotes
Managers TitleAgeSince
Founder 56 07-12-31
Chief Executive Officer 45 16-05-31
Director of Finance/CFO 46 22-07-31
Members of the board TitleAgeSince
Director/Board Member 58 21-12-31
Director/Board Member 48 21-12-31
Founder 50 07-12-31
More insiders
Date Price Change Volume
24-04-26 282 +1.81% 9,608
24-04-25 277 -5.78% 20,869
24-04-24 294 +0.34% 17,403
24-04-23 293 +3.53% 20,489
24-04-22 283 0.00% 8,653

Delayed Quote Nasdaq Copenhagen, April 26, 2024 at 10:59 am EDT

More quotes
Gubra A/S is a Denmark-based biotechnology company specialized in high-end pre-clinical contract research and peptide-based drug discovery within metabolic and fibrotic diseases. The Company’s operations are anchored around its advanced technology platforms and utilization of automation, robotization and digitalization, including machine learning (ML) and artificial intelligence (AI). The Company's business activity are divided into two segments: The CRO Segment offers specialized profitable pre-clinical contract research services at attractive margins within metabolic and fibrotic disease areas such as diabetes, obesity, chronic kidney disease; and The Discovery and Partnership Segment is based on an internal target and drug discovery engine for identification and design of peptide-based drug partnering candidates within metabolic and fibrotic diseases.
More about the company